Mainz Biomed N.V. has announced a partnership with Quest Diagnostics to commercialize its stool-based colorectal cancer screening test, ColoAlert, which detects tumor DNA to identify early-stage ...
BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the ...
From expanding partnerships to advancing trials, Mainz Biomed NV (NASDAQ:MYNZ), the molecular genetics diagnostic company, had a busy 2024 – which appears to have shown in its revenue growth. The ...
BERKELEY, Calif. and MAINZ, Germany, March 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early ...
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test 19.12.2024 / 14:00 CET/CEST The issuer is solely responsible for ...
BERKELEY, US and MAINZ, Germany – December 19, 2024-- Mainz Biomed N.V. MYNZ ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results